IDStewardship

JUNE 19, 2025

Despite advancements in treatment, certain patients may exhibit delayed responses, have drug-resistant TB, be at risk for drug-drug interactions, or have comorbid conditions that considerably complicate clinical management. Geneva, World Health Organization, 2020. N Engl J Med. 2011;365(23):2155–2166. World Health Organization.

HIV Treatment and Prevention Agents 130

HIV Treatment and Prevention Agents Adverse Reactions Dosage Labelling 130

ISPE

OCTOBER 27, 2022

There are important considerations if the DHTT is classified as a medical device, which may change the level of regulatory controls and evidentiary requirements to support its appropriate use, such as off-label versus on-label use of a device with prior marketing authorization. Published 2 October 2020. Updated October 2020.

Health and Personal Care Stores 52

Health and Personal Care Stores FDA HIPAA Communication 52

ISPE

OCTOBER 27, 2022

There are important considerations if the DHTT is classified as a medical device, which may change the level of regulatory controls and evidentiary requirements to support its appropriate use, such as off-label versus on-label use of a device with prior marketing authorization. Published 19 October 2020. Published 1 June 2020.

Health and Personal Care Stores 52

Health and Personal Care Stores FDA Communication Clinic Management 52